European Patent Office (EPO) President António Campinos has done absolutely nothing to undo Battistelli's attacks on the autonomy of EPO judges. Nothing! To make matters worse, Campinos is already meddling in upcoming/ongoing cases, including one that shapes EPO policy on software patents in Europe. So one might say that Campinos is no different -- or potentially worse -- than Battistelli.
The December issue 4|2019 of the journal epi Information contains four interesting contributions to the discussion on the novelty test for sub-ranges as used by the EPO.
The EPO has a special novelty test to determine whether a claimed numerical sub-range of a known broad range is novel over the known range. A sub-range must comply with each of the three criteria of the test. The criteria are, that the sub-range (i) must be narrow compared to the broad range, (ii) be far removed from known examples within the broad range, and (iii) is not an arbitrary specimen of the prior art but another invention (purposive selection, new technical teaching).
The test was formulated in 1985 by the technical board of appeal in decision T198/84 and subsequently used broadly within the EPO. Recently, several articles have criticized the test. In 2013 Thomas Leber of the EPO regarded compliance of the three criteria with the EPC questionable (see JIPLP, vol. 8, issue 7, July 2013, pages 561-565). More recently, I argued that the three criteria are incompatible with recent EPO case law on novelty (epi Information, issue 4|2019, page 27-33).
The latest edition of the Guidelines for Examination in the EPO, which entered into force on 1 November 2019, has removed the purposive selection criterion from the test (see section G-VI, 8(ii)). However, the latest edition of the book Case Law of the Boards of Appeal of the European Patent Office, 9th edition, published July 2019, still mentions the three criteria of the test (see chapter I.C.6.3.1). In addition, the book mentions a large body of contradictory case law about the purposive selection. Roel van Woudenberg argues in his recent article, that the purposive selection criterion should be kept in the test, as being consistent with the disclosure test used for novelty (see epi Information, issue 4|2019, page 34-39).
[...]
The above course of events shows that only because the President of the epi had written a letter to the EPO, did users of the EPC learn about the development of the case law and the adoption of the two-part test by most boards of appeal. If the President of the epi had not submitted his request, the users of the EPC would still be unaware of the development of the case law and, as a consequence, would still be uncertain about what test for novelty of a sub-range to use in appeal cases.
According to the European Patent Institute (EPI), the law on the novelty of selection inventions is unclear, given the diverging opinions of the Boards of Appeal. In view of this purported lack of clarity, the EPI president (Francis Leyder) wrote a letter to the President of the EPO requesting the President to refer the issue to the EBA. The President of EPI cited a number of recent Boards of Appeal decisions that did not apply the “purposive selection" criteria (including T 1233/05, T 1131/06, T 230/07, T 1130/09, T 2041/09, T 378/12 and T 1404/14) and a two recent decisions that did (T 66/12 and T 673/12). In the view of EPI “[i]t is clear from the above that there are clearly two incompatible lines of Board of Appeal decision as to what are the criteria to be used in deciding whether a sub-range is novel”. The President of EPI therefore suggested a referral from the EPO President to the EBA, that might ask the following question:
“What are the criteria to be used in assessing the novelty of a claim where the allegedly distinguishing feature of the claim relative to a prior art document is a sub-range of a broader range disclosed in that prior art document”.
[...]
It seems that proponents of a referral with respect to selection inventions can now only hope for a referral by a Board of Appeal (Article 112(1) EPC). Indeed, EPI urges parties in appeal proceedings who find themselves involved in a case where the use or not of the “purposive selection” criteria is influential to the case, to request the Board to refer the issue to the EBA. The opposing view is that a referral is not necessary, as the Boards of Appeal do seem to be following the approach now set out by the guidelines. Indeed, Roel van Woudenberg could be said to be pushing the issue merely because he disagrees with the removal of the purposive selection criteria (as argued his article cited by EPI).
Selection inventions have always been a hotly debated issue. In another article cited by EPI, authored by Derk Visser, it is argued that all three criteria listed in the guidelines are inconsistent with recent case law on novelty. As with second medical use inventions (another form of selection invention), critics are keen that an inventor should not “get something for nothing” by salami slicing (or as some-would have it, “sashimi slicing”) the prior art. The boarder question surrounding the EPI recent request for a referral on sub-ranges is whether the EPO is currently striking the right balance on selection inventions. What do readers think?
Robin Jacob has been known to advise audiences that "We can learn a lot from the Americans. Watch carefully what they do. And then make sure not to make the same mistake that they did."
Observing what the Supreme Court of the USA does to patent law, one might think that, over here, a reference to the EBA can sometimes be premature.
As here, I think. The case law of the EPO emerges like Darwinian evolution. I mean, survival of the "fittest" line of legal logic. Is that not how the best EBA case law has emerged, over the last 40 years? It will do so here, I would think.
Sometimes patience is called for. Given time, things will all work out for the best. Meanwhile, our advocacy skills will decide which of the rival lines will prevail. For me, the "seriously contemplate" test can be reconciled with the Gold Standard, and makes a lot of sense.
Thanks to egna for that suggestion of a contest between Dworkian and Hartian schools of thought. I must say, that had not occurred to me but I daresay he has his finger on the point.
egna also flags up the difficulties faced by EQE candidates. Quite right too. But in the greater scheme of things, we are talking about the rather short 18 month period covered by Art 54(3) and industry uncertainty about prior art generated within that brief period. That's not the largest source of legal uncertainty in patent law in EPC land, is it?
Personally, I think the bigger mischief lies in deciding obviousness according to a rubric written differently in the Supreme Court of each separate national jurisdiction of the 38 EPC Member States. Why can't they all accept the established case law of the Boards of Appeal of the EPO, as they do (more or less) already on other repercussions that derive, directly and unambiguously, from acceptance the EPO's "Gold Standard".
Well that's indeed the thing, isn't it, Attentive. Consider the skilled person, interested in the "disclosure" of a document, wanting to milk it for everything derivable from it. The Gold Standard limits the "disclosure" to that which is "derivable" directly and unambiguously, from the document. But the imaginary addressee has at its disposal, to assist in the task of deriving stuff, all the common general knowledge that can be imputed to the hypothetical skilled person. Under those conditions, what the skilled person is deemed to seriously contemplate during the contemplation of the document can be seen as within the ambit of that which the skilled person derives, directly and unambiguously, from the document.
Or, to put it another way, when one deems the skilled person to be the possessor of an enormous reservoir of common general knowledge, one necessarily imputes to that imaginary being subject matter that it cannot help but "contemplate" seriously and inevitably, when performing the task of deriving disclosure from the document.
Or, to put it another way, is not the "implicit" disclosure and what the reader will "seriously contemplate" two ways of expressing much the same thought?
After all, we here in Europe do need a pragmatic solution to the "Art 54(3) art" problem which balances the need for fair protection, as between the earlier and the later Applicant, with reasonable legal certainty for the public. The AIA solution in the USA, in making all 54(3) art available for obviousness attacks, fails that test by giving too much power to the first filer. Rendering nugatory any 54(3) attacks on later filings awards too much protection to the later filer, and enables anti-social evergreening by bulk filers. A golden middle way is needed.
In a landmark ruling, the European Patent Office (EPO) has rejected two patent applications[1] wherein request was lodged with the EPO for designating machine (Artificial Intelligence) as an “inventor”[2].
The ground cited for rejecting the aforementioned patent applications is that the patent applications did not meet the requisite requirement as enumerated under the EPC that an inventor designated in the application should be a human being, not a machine.
The above artificial intelligence inventor namely, “DABUS” has been in news ever since patent applications were filed with the EPO on behalf of DABUS. DABUS has been invented by Dr Stephen Thaler, Founder & Board Chairman at Imagitron, LLC.